Co-founder and CEO Sophie James on modified monosaccharides, intracellular glycan processing, and a rare-disease-first route into fibrosis, oncology, and Alzheimer's.
New options emerged in PBC-associated itch, plaque psoriasis, neurologic Hunter syndrome, and platinum-resistant ovarian cancer.
Deal brings Exl-111 into Novartis’s allergy portfolio, targeting IgE-driven diseases including food allergy and asthma.
Merck has agreed to acquire Terns Pharmaceuticals for $53.00 per share in cash, adding Phase 1/2 CML candidate TERN-701 to its hematology pipeline.
Sanofi will obtain exclusive worldwide rights to Kali Therapeutics’ KT501 under an agreement covering a tri-specific T-cell engager for B cell-mediated autoimmune diseases.
The accelerated approval in Hunter syndrome was supported by Phase 1/2 biomarker data and adds a Priority Review Voucher alongside Denali’s first approved blood-brain barrier-penetrant biologic.
Corcept’s FDA approval establishes relacorilant as the first FDA-approved selective glucocorticoid receptor antagonist
Lupin gained semi-exclusive rights to co-market Zydus’ semaglutide injection in India, while Sun Pharma launched Noveltreat and Sematrinity for chronic weight management and type 2 diabetes.
Rhythm Pharmaceuticals said the FDA approved IMCIVREE for acquired hypothalamic obesity, making it the first FDA-approved therapy for the condition.
The deal increases Abbott’s exposure to a U.S. cancer screening and precision oncology diagnostics market the company sizes at $60 billion.
The FDA issued a Complete Response Letter for Aldeyra’s reproxalap application in dry eye disease, citing insufficient evidence of efficacy and inconsistent trial results.
On March 17, 2026, the FDA approved Johnson & Johnson’s ICOTYDE (icotrokinra) for adults and pediatric patients 12 years and older who weigh at least 40 kg with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ICOTYDE is a once-daily oral IL-23
On March 17, 2026, the US FDA approved Lynavoy (linerixibat) for cholestatic pruritus associated with primary biliary cholangitis. The approval came days after GSK and Alfasigma announced a March 9 licensing agreement under which Alfasigma acquired exclusive worldwide rights to develop, manufacture, and commercialize linerixibat. Under the agreement, GSK receives
The FDA approval extends Cosentyx into pediatric hidradenitis suppurativa, with use supported by adult studies, pharmacokinetic modeling, and pediatric data from other approved indications
The approved NEO system is designed to restore hand-grasping ability through neural signal decoding and a robotic glove.
Eli Lilly said testing found an impurity in compounded tirzepatide products mixed with vitamin B12 and urged FDA action.
